Nykode Therapeutics ASA
OTC:VACBF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nykode Therapeutics ASA
OTC:VACBF
|
NO |
|
Tivoli A/S
CSE:TIV
|
DK |
|
Comsys Holdings Corp
F:CS7
|
JP |
|
Lawfinance Ltd
ASX:LAW
|
AU |
|
S
|
Semen Indonesia (Persero) Tbk PT
F:SMS2
|
ID |
|
Salt Lake Potash Ltd
ASX:SO4
|
AU |
|
Propell Holdings Ltd
ASX:PHL
|
AU |
|
C
|
Coded Growth Innovation Center Inc
OTC:DMSI
|
US |
|
N
|
Namyong Terminal PCL
SET:NYT
|
TH |
|
E
|
Efficient E-Solutions Bhd
KLSE:EFFICEN
|
MY |
|
Accelerated Technologies Holding Corp
OTC:ATHC
|
US |
|
E
|
Etrend Hightech Corp
TPEX:3567
|
TW |
|
N
|
Newrange Gold Corp
F:X6C
|
CA |
|
Kansai Electric Power Co Inc
OTC:KAEPF
|
JP |
|
Orex Minerals Inc
OTC:ORMNF
|
CA |
|
Aeria Inc
TSE:3758
|
JP |
|
Docebo Inc
F:061
|
CA |
Bankruptcy Probability
Nykode Therapeutics ASA's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Nykode Therapeutics ASA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NO |
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
1.3B NOK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
462.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
233.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
136.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
56.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
80.6B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Nykode Therapeutics ASA's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Nykode Therapeutics ASA has total debt of 1.3m USD. This includes both short-term (0 USD) and long-term (1.3m USD) debt.
You can find a full breakdown on its Balance Sheet.
